count source_label source_id relationship target_label target_id entity_type solr_id publication_id sentences 24 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype a500c36e-3812-11e6-aaca-001a4ae51246 PMC4367286 Zoxazolamine-induced Paralysis Zoxazolamine-induced paralysis ofAbcb6+/+andAbcb6−/−mice was determined after animals were injected with a single intraperitoneal dose of zoxazolamine (300 mg·|||Zoxazolamine-induced paralysis ofAbcb6+/+andAbcb6−/−mice was determined after animals were injected with a single intraperitoneal dose of zoxazolamine (300 mg· 18 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype 36742196-3777-11e8-a34b-001a4a160175 15707772 The results show that pentobarbital-induced sleeping and zoxazolamine-induced paralysis times of the control group were not significantly different from the ADD-199 treated group (p>0.05).|||The effect of pre-treatment of rats with ADD-199 (500mg/kg/day) for 30 days on pentobarbital-induced sleeping and zoxazolamine-induced paralysis times are shown inTable 5.|||Studies have shown that pre-treatment of rats with PB and 3-MC induced CYP 2B/2E and CYP 1A/2A/2E, respectively; thereby decreasing pentobarbital-induced sleeping or zoxazolamine-induced paralysis times (Pratt and Taylor, 1990).|||In a similar study with mice, the aqueous extract ofIndigofera arrectaneither modulated the hepatic microsomal activities of EROD, PROD and PNPH nor changed the pentobarbital-induced sleeping and zoxazolamine-induced paralysis times when compared to controls (Nyarko et al., 1999).|||Pentobarbital sleeping and zoxazolamine paralysis times and monooxygenase activities The effect of pre-treatment of rats with ADD-199 (500mg/kg/day) for 30 days on pentobarbital-induced sleeping and zoxazolamine-induced paralysis times are shown inTable 5.|||In vivo drug interaction was assessed by the pentobarbital-induced sleeping time and the zoxazolamine-induced paralysis time as described previously (Nyarko et al., 1999).|||Pentobarbital sleeping and zoxazolamine paralysis times In vivo drug interaction was assessed by the pentobarbital-induced sleeping time and the zoxazolamine-induced paralysis time as described previously (Nyarko et al., 1999).|||ADD-199, in this study, did not alter the pentobarbital-induced sleeping and zoxazolamine-induced paralysis times. 16 FPLX:CYP inhibits Zoxazolamine MESH:D015049 ProteinFamily a500c36e-3812-11e6-aaca-001a4ae51246 PMC4367286 Zoxazolamine, a muscle relaxant, is inactivated by CYP enzyme activity with a preference for Cyp2b10 and like pentobarbital is traditionally used as anin vivomeasure of altered P450 activity (45). 16 UNIPROT:P12791 inhibits Zoxazolamine MESH:D015049 Protein a500c36e-3812-11e6-aaca-001a4ae51246 PMC4367286 Zoxazolamine, a muscle relaxant, is inactivated by CYP enzyme activity with a preference for Cyp2b10 and like pentobarbital is traditionally used as anin vivomeasure of altered P450 activity (45). 12 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype 8f068336-3947-11e8-9fbf-001a4a160176 17291700 To study zoxazolamine induced paralysis time grouping of the animals and treatment is same except for the dose of zoxazolamine, which was 70mg/kg, ip.|||Hexobarbitone induced narcosis and zoxazolamine induced paralysis time in mice Hexobarbitone sleep time and zoxazolamine induced paralysis time were significantly (P<0.001) raised in CCl4treated animals.|||Hexobarbitone induced narcosis and zoxazolamine induced paralysis time Six groups of mice with six mice in each group were used for each study.|||Hexobarbitone sleep time and zoxazolamine induced paralysis time were significantly (P<0.001) raised in CCl4treated animals.|||Results Hexobarbitone sleep time and zoxazolamine induced paralysis time were significantly (P<0.001) raised in CCl4treated animals. 7 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype 121daec0-c479-11e5-9cc6-001a4ae51246 PMC3232307 Knockout of SRC-3 in mice exacerbates zoxazolamine-induced paralysis To determine that the critical role of SRC-3 in CAR-mediated drug metabolism is not limited to APAP, we performed zoxazolamine-induced paralysis experiments in wild-type,SRC-3+/−, andSRC-3−/−mice.|||We found that knockout ofSRC-3in mice reduced TCPOBOP-induced hepatocyte hyperplasia, abrogated TCPOBOP-induced APAP hepatotoxicity, and exacerbated zoxazolamine-induced paralysis.|||We found thatSRC-3-deficient mice exhibited reduced TCPOBOP-induced hepatocyte hyperplasia, abrogated TCPOBOP-induced APAP hepatotoxicity, and exacerbated zoxazolamine-induced paralysis compared to their wild-type controls.|||As shown inTable 1, under normal physiological condition, injection of zoxazolamine caused paralysis in all mice.|||Therefore, wild-type,SRC-3+/−, andSRC-3−/−mice displayed SRC-3 dosage-dependent susceptibility to zoxazolamine-induced paralysis, further demonstrating that SRC-3 plays an important role in CAR-mediated hepatic drug metabolism.|||Zoxazolamine, a muscle relaxant that causes paralysis, can be detoxified by CAR-regulated hepatic CYP enzymes such as CYP1A2[23], so mice can recover from zoxazolamine-induced paralysis after clearance of zoxazolamine. 6 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype 57a7f91a-393d-11e8-87fd-001a4a160176 18639619 Hexobarbitone induced sleep time and zoxazolamine induced paralysis time Six groups of mice with six mice in each group were used for each hexobarbitone induced sleep time and zoxazolamine induced paralysis time.|||) sleep time and zoxazolamine induced paralysis time (70mg/kg, i.p.|||WF4 showed significant recovery in hexobarbitone sleep time and zoxazolamine induced paralysis time.|||) counteracts CCl4(p<0.001) enhanced sleep and zoxazolamine induced paralysis time exhibiting dose-dependent hepatoprotective activity.|||Induction of liver injury Liver injury was induced by administration of 1% carbon tetrachloride (CCl4) diluted with liquid paraffin for hexobarbitone induced sleep time and zoxazolamine induced paralysis time whereas dilution was 20% in rest of studies. 6 Zoxazolamine MESH:D015049 activates UNIPROT:Q9H2S1 Protein a6cbe050-cb27-11e5-b419-001a4ae51246 11181893 "Moreover, NS 1619 also inhibited the rSK2 channel currents activated by chlorzoxazone, 1-EBIO, and zoxazolamine.|||When applied externally chlorzoxazone, 1-EBIO, and zoxazolamine activated rSK2 channels in cells dialyzed with a nominally Ca2+-free intracellular solution.|||In conclusion, we have shown that chlorzoxazone, 1-EBIO, and zoxazolamine activate recombinant rat brain SK2 channels in a Ca2+-independent manner.|||First, chlorzoxazone and the structurally related compounds 1-EBIO and zoxazolamine activate recombinant rSK2 channels when applied extracellularly.|||Instead, this compound inhibited rSK2 channel currents activated by either chlorzoxazone, 1-EBIO, zoxazolamine, or elevated intracellular Ca2+.|||Chlorzoxazone, 1-EBIO, and zoxazolamine activated rSK2 channel currents in a concentration-dependent manner." 4 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype cbf7bf5c-c46f-11e5-8491-001a4ae51247 PMC4156578 Other Methods Liver function was assessed with the Zoxazolamine-induced paralysis test as described in theSupplemental Information(Zhang and Cuervo, 2008).|||Liver function was assessed with the Zoxazolamine-induced paralysis test as described in theSupplemental Information(Zhang and Cuervo, 2008). 3 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype 428aeb56-3b62-11e8-b868-001a4a160176 PMC5871315 The administration ofD adscendensextract decreased zoxazolamine-induced paralysis time and thiopentone-induced sleeping time.|||While chronic administration of the plant extract was nontoxic,D adscendensshowed a potential to cause herb-drug interaction, which was demonstrated in the alteration of zoxazolamine-induced paralysis time, thiopentone-induced sleeping time, and liver CYP isozymes activities, when the medicinal plant is administered with other drugs.|||Herb-Drug Interaction Determination The effect of the plant extract on the duration of sleep induced by thiopentone and paralysis induced by zoxazolamine was investigated following the procedures previously described.16Two groups of animals, one serving as a test group and the other as control, were used to investigate thiopentone-sleeping time, and 2 other groups (test and control) were used to investigate zoxazoleamine paralysis time. 2 Zoxazolamine MESH:D015049 activates UNIPROT:O94907 Protein 9aa77a3c-bc4a-11e5-9b9d-001a4ae51247 10.1016/S0014-2999(02)01987-8 Third, riluzole has some structural similarity to compounds such as chlorzoxazone, 1-EBIO, and zoxazolamine that modulate native and recombinant SK channels(Cao et al., 2001; Pedarzani et al., 2001). 2 Zoxazolamine MESH:D015049 activates UNIPROT:P36575 Protein 0756d800-c9ff-11e5-be63-001a4ae51246 15358766 Because CAR is inactive under basal circumstances, this suggests that zoxazolamine may activate CAR and thereby increase its own clearance. 2 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype 1e6ad850-ca01-11e5-b88f-001a4ae51247 PMC1187948 "Loss of PBP Expression on Zoxazolamine Paralysis and APAP Hepatotoxicity.The essentiality of coactivator PBP in CAR-mediated transcription was further confirmed by the assessment of muscle relaxant zoxazolamine-induced paralysis and APAP hepatotoxicity (21,23).|||Likewise, 7/8 PBPLiv-/-mice pretreated with PB also died after zoxazolamine-induced paralysis." 2 UNIPROT:O75469 activates Zoxazolamine MESH:D015049 Protein 0756d800-c9ff-11e5-be63-001a4ae51246 15358766 Previous results show that prior activation of either CAR or PXR strongly increases the rate of zoxazolamine clearance (6,7). 2 UNIPROT:P36575 activates Zoxazolamine MESH:D015049 Protein 0756d800-c9ff-11e5-be63-001a4ae51246 15358766 Previous results show that prior activation of either CAR or PXR strongly increases the rate of zoxazolamine clearance (6,7). 1 Zoxazolamine MESH:D015049 activates UNIPROT:P00918 Protein a6cbe050-cb27-11e5-b419-001a4ae51246 11181893 "In conclusion, we have shown that chlorzoxazone, 1-EBIO, and zoxazolamine activate recombinant rat brain SK2 channels in a Ca2+-independent manner." 1 Zoxazolamine MESH:D015049 activates GO:0030431 Phenotype dc572276-c478-11e5-85e4-001a4ae51246 PMC3156825 Interestingly, we find that sleep time induced by Zoxazolamine was not altered by HFD; this finding is in agreement with the fact that HFD had no effect on the RNA levels of Cyp1a2 and Cyp2e1, the main enzymes involved in Zoxazolamine metabolism (Fig. 7B). 1 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype dace64ac-bee5-11e5-babb-001a4ae51247 10.1016/j.taap.2009.11.005 Consistent with our previous report that ginsan prolongs zoxazolamine-induced paralysis due to decrease in CYP450 activity (Song et al., 2004), suppression of CYP2E1 by ginsan was observed in this experimental model (Fig. 3B). 1 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype d82717aa-cb27-11e5-9aa0-001a4ae51247 11353134 "Doses of 3′M4′NF in the 0.2- to 2-mg/kg range, as used in the present studies, were found to have no measurable effect on zoxazolamine-induced paralysis time (Dertingeret al., 2001)." 1 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype ff313fa8-c8eb-11e5-878b-001a4ae51247 PMC2798732 Zoxazolamine-induced paralysis in NP-treated mice Wild-type male and female mice were randomly split into treatment groups. 1 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype dc572276-c478-11e5-85e4-001a4ae51246 PMC3156825 Therefore, to further substantiate our findings, we determined the effect of obesity on the duration of sleep time induced by Midazolam, which is predominantly metabolized by Cyp3a, and the paralysis time induced by Zoxazolamine, which is primarily metabolized by Cyp1a2 and Cyp2e1 (Liang et al., 1996; Olkkola and Ahonen, 2008). 1 Zoxazolamine MESH:D015049 inhibits MESH:D010243 Phenotype 57a7f91a-393d-11e8-87fd-001a4a160176 18639619 The damage inflicted by CCl4on hepatocytes causes a loss of drug metabolizing enzymes of the liver (Anand et al., 1997) which results in the prolongation of sleep time and zoxazolamine induced paralysis time (Fujimoto et al., 1960; Janbaz and Gilani, 1995). 1 Zoxazolamine MESH:D015049 activates MESH:D010243 Phenotype e029233a-ac4f-11e6-a286-001a4ae51247 PMC4897414 ) significant hepatoprotective activity against carbon tetrachloride-induced liver injury in rats and mice as determined through various tests like hexobarbitone-induced sleep, zoxazolamine-induced paralysis, bromsulfalein (BSP) clearance, serum levels of transaminases, bilirubin, and protein [47]. 1 UNIPROT:P01189 activates Zoxazolamine MESH:D015049 Protein 8b2ae69a-5c2e-11e7-8b40-001a4ae51247 28218677 From the results shown inTable 8, it can be concluded that ACTH augments drug resistance to zoxazolamine and this could be attributed to both a small induction of drug metabolising hepatic enzymes, but further, and probably mainly, to increased body tolerance to zoxazolamine. 1 CHEBI:18009 inhibits Zoxazolamine MESH:D015049 Chemical 428aeb56-3b62-11e8-b868-001a4a160176 PMC5871315 Nicotinamide adenine dinucleotide phosphate (reduced) (NADPH), resorufin, 7-ethoxyresorufin, 7-pentoxyresorufin, zoxazolamine (2-amino-5-chlorobenzoxazole), bovine serum albumin (BSA), and perchloric acid were obtained from Sigma Chemical Co (St Louis, MO, USA). 1 UNIPROT:Q14994 activates Zoxazolamine MESH:D015049 Protein 4b0930c6-ab1c-11e6-807f-001a4ae51247 PMC5054525 These findings are in agreement with a previous report, where the constitutive androstane receptor ligand TCPOBOP elicited epigenetic memory at theCyp2b10promoter and increased zoxazolamine metabolism and hepatocyteCyp2b10transcription memory27. 1 CHEBI:42491 activates Zoxazolamine MESH:D015049 Chemical 44a5185a-cb28-11e5-8189-001a4ae51246 11717184 "There are few examples of this phenomenon in vivo, but flavone-dependent activation of zoxazolamine metabolism has been observed in rats (Lasker et al., 1982), and quinidine has been shown to activate CYP3A4-mediated diclofenac metabolism in monkeys (Tang et al., 1999)." 1 CHEBI:42491 activates Zoxazolamine MESH:D015049 Chemical 81f4b1c0-cbf0-11e5-a19a-001a4ae51247 10565826 "In one case, a flavone-dependent enhancement of zoxazolamine metabolism in rats was reported, but the affected enzyme system was not characterized (Lasker et al., 1982)." 1 MESH:D008024 activates Zoxazolamine MESH:D015049 Phenotype 4b0930c6-ab1c-11e6-807f-001a4ae51247 PMC5054525 These findings are in agreement with a previous report, where the constitutive androstane receptor ligand TCPOBOP elicited epigenetic memory at theCyp2b10promoter and increased zoxazolamine metabolism and hepatocyteCyp2b10transcription memory27. 1 UNIPROT:P36575 inhibits Zoxazolamine MESH:D015049 Protein 77381e5e-c8dd-11e5-a1fd-001a4ae51246 PMC1422155 From a physiological perspective, loss of CAR in the mouse increases sensitivity to zoxazolamine‐induced paralysis, while decreasing sensitivity to acetaminophen or cocaine‐induced acute hepatic response (Weiet al, 2000;Zhanget al, 2002). 1 UNIPROT:P05177 inhibits Zoxazolamine MESH:D015049 Protein 1e6ad850-ca01-11e5-b88f-001a4ae51247 PMC1187948 "CYP enzymes CYP1A2 and CYP2E1 metabolically inactivate zoxazolamine, and induction of CYP1A2, in particular, by certain xenobiotics, including CAR ligands, leads to rapid metabolic inactivation of zoxazolamine, resulting in decreased duration of paralysis (18,23)." 1 UNIPROT:P05181 inhibits Zoxazolamine MESH:D015049 Protein 1e6ad850-ca01-11e5-b88f-001a4ae51247 PMC1187948 "CYP enzymes CYP1A2 and CYP2E1 metabolically inactivate zoxazolamine, and induction of CYP1A2, in particular, by certain xenobiotics, including CAR ligands, leads to rapid metabolic inactivation of zoxazolamine, resulting in decreased duration of paralysis (18,23)."